Alexion Pharmaceuticals, Inc. (ALXN) SVP Heidi L. Wagner Sells 1,774 Shares
Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) SVP Heidi L. Wagner sold 1,774 shares of the firm’s stock in a transaction on Thursday, February 8th. The stock was sold at an average price of $116.31, for a total transaction of $206,333.94. Following the sale, the senior vice president now owns 47,212 shares in the company, valued at $5,491,227.72. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.
Shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) traded down $0.45 during trading hours on Friday, hitting $108.02. 910,061 shares of the stock traded hands, compared to its average volume of 1,989,519. The firm has a market cap of $26,172.44, a PE ratio of 48.33, a PEG ratio of 0.98 and a beta of 1.16. The company has a quick ratio of 2.51, a current ratio of 2.96 and a debt-to-equity ratio of 0.35. Alexion Pharmaceuticals, Inc. has a one year low of $96.18 and a one year high of $149.34.
Alexion Pharmaceuticals (NASDAQ:ALXN) last announced its quarterly earnings results on Thursday, February 8th. The biopharmaceutical company reported $1.48 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.09 by $0.39. The company had revenue of $909.70 million for the quarter, compared to analyst estimates of $880.38 million. Alexion Pharmaceuticals had a net margin of 14.57% and a return on equity of 12.55%. The firm’s revenue was up 9.5% on a year-over-year basis. During the same period in the previous year, the firm posted $1.26 EPS. sell-side analysts forecast that Alexion Pharmaceuticals, Inc. will post 4.82 EPS for the current fiscal year.
A number of research analysts recently weighed in on the stock. Evercore ISI raised shares of Alexion Pharmaceuticals from an “in-line” rating to an “outperform” rating in a research report on Monday. Citigroup decreased their target price on shares of Alexion Pharmaceuticals from $173.00 to $170.00 and set a “buy” rating for the company in a research report on Friday. Deutsche Bank set a $161.00 price objective on shares of Alexion Pharmaceuticals and gave the company a “buy” rating in a research report on Friday. Leerink Swann decreased their price objective on shares of Alexion Pharmaceuticals from $166.00 to $153.00 and set an “outperform” rating for the company in a research report on Friday. Finally, Morgan Stanley lifted their price objective on shares of Alexion Pharmaceuticals from $148.00 to $151.00 and gave the company an “overweight” rating in a research report on Friday. One investment analyst has rated the stock with a sell rating, two have given a hold rating and twenty-one have assigned a buy rating to the company. The stock has an average rating of “Buy” and an average price target of $153.18.
TRADEMARK VIOLATION WARNING: This piece of content was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this piece of content on another publication, it was stolen and republished in violation of U.S. and international trademark and copyright laws. The correct version of this piece of content can be viewed at https://www.thecerbatgem.com/2018/02/09/alexion-pharmaceuticals-inc-alxn-svp-heidi-l-wagner-sells-1774-shares.html.
Alexion Pharmaceuticals Company Profile
Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).
Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.